Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

Last week, the Food and Drug Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name Mounjaro for diabetes and Zepbound for obesity. The move was a ...

Also Read: Eli Lilly’s Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron’s Dupixent In the LUCENT-3 trial, mirikizumab helped patients ...

Nico Chen has given his Buy rating due to a combination of factors including Eli Lilly’s strong revenue growth and the potential expansion of its diabetes medication Mounjaro. Chen recognizes ...

Coming off a brutal 41-10 loss to Texas A&M, Missouri head coach Eli Drinkwitz was eager to see the way his team would respond. Here's all he had to say after the team's win to round out its non ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

Lake's Daniela Scheffler and Jackson's Eli Ilg are the 2024 Federal League Cross Country Runners of the Year. Scheffler set school and Jackson Middle Course with a winning time of 16:41.86 in the ...

The high court heard arguments Thursday morning on Attorney General Dana Nessel’s effort to investigate and potentially sue the drug company Eli Lilly on the grounds that its insulin pricing ...

Speaking shortly after his firm announced it “anticipates making £279m investment over three years” in the UK life sciences sector, Eli Lilly chief executive David Ricks warned that due to ...